EyeMed
EyeMed is a vision insurance plan owned by EssilorLuxottica, offering employer-sponsored and individual vision benefits to tens of millions of members. The plan covers eye exams, frames, lenses, and contact lenses through a network that includes independent eye doctors and prominently features EssilorLuxottica-owned retail chains including LensCrafters, Pearle Vision, and Target Optical.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-26. Score revised 2026-09-26: 62 → 53.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Luxottica launches EyeMed Vision Care as its managed vision care subsidiary (EyeMed itself dates its business to 1988, but company histories place the subsidiary's launch in 1999), four years after buying LensCrafters. In 2001 it buys First American Health Concepts for $23.5 million and raises exam fees about 25% to compete with VSP for providers. The insurer-plus-retailer model is in place, but EyeMed is still building scale and its network is anchored by a single parent-owned chain.
Luxottica's purchase of Cole National adds Pearle Vision, the Target and Sears optical departments and Cole Managed Vision, which is folded into EyeMed by October 2005, so the parent's chains now dominate the in-network storefronts. Luxottica buys Oakley in 2007 after squeezing it through Sunglass Hut, and EyeMed grows into the second-largest U.S. vision benefits company. Independent optometrists increasingly compete with their own supplier's stores for EyeMed patients, while 60 Minutes (2012) brings the hidden ownership web to public attention.
EssilorLuxottica is formed after the FTC closes its review without conditions, joining the largest lens maker to Luxottica's frames, retail chains and EyeMed. The insurer now sits atop a chain that runs from lens manufacturing to point of sale. A 2019 power struggle between Del Vecchio and former Essilor chief Hubert Sagnieres exposes governance strains in the combined group.
A phishing attack on a shared EyeMed mailbox exposes 2.1 million members' health data, leading to state penalties in 2022-2023. Antitrust class actions filed in 2023 and 2024 name EyeMed and allege it steers patients and providers toward EssilorLuxottica eyewear, while an AOA poll finds 40% of optometrists see EyeMed as the biggest barrier to care. The parent absorbs GrandVision, faces an OECD complaint over anti-union tactics, puts the Chairman and CEO roles in one person after Del Vecchio's 2022 death, and steps up buybacks.
The AOA formally accuses EyeMed of clawbacks, tying and bad faith, and weeks later a federal court dismisses the consumer antitrust suits against EssilorLuxottica. EyeMed then presses Arkansas optometrists to sign new agreements while arguing the state's new Medicare-based pay floor does not apply to routine exams. The breach litigation ends with final approval of a $5 million settlement in September 2026, as the parent posts record results, launches a new buyback and faces a public rift with the founder's son.
Alternatives
Founded in 2010 as a low-cost alternative in a Luxottica-dominated industry, Warby Parker sells complete prescription glasses starting at $95, cheap enough that skipping vision insurance and paying out of pocket can cost less than premiums plus copays. It had more than 300 stores at the end of 2025, many offering eye exams. Works well for people whose EyeMed benefits mostly flow back to EssilorLuxottica-owned retailers anyway.
One of the two largest U.S. vision benefits companies, and not owned by EssilorLuxottica. VSP is not conflict-free: it is affiliated with the Visionworks optical chain and owns a lens business (VSP Optics) and the frame maker Marchon Eyewear. Still, if your employer offers both EyeMed and VSP, choosing VSP moves your benefits outside EssilorLuxottica's loop of insurer, retailer and manufacturer. VSP also sells individual plans directly. The catch: most people can't choose their employer's vision plan offerings.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (56 events)
Luxottica Signs First Designer Licensing Deal (Giorgio Armani)
Luxottica signs its first designer licensing agreement, with Giorgio Armani, beginning a model in which Luxottica designs and manufactures eyewear sold under fashion-house names while its own name stays off the product. Consumers buying designer frames generally cannot tell who made them, an opacity that later extends to EyeMed, where plan members could not easily see that the in-network retailers, the frame maker and their insurer were the same company.
EyeMed's Stated Founding Year
EyeMed says it has operated since 1988 and presents itself as part of the Luxottica family of companies. Luxottica did not own a U.S. retail chain until it bought LensCrafters in 1995, and company histories date its launch of the EyeMed Vision Care subsidiary to 1999, so what EyeMed's business looked like in 1988, and who owned it, is not documented in the sources reviewed.
Luxottica Lists on NYSE as First Italian Company
Luxottica floats 23% of its equity on the New York Stock Exchange as American Depositary Receipts, the first Italian company to list on the NYSE without first listing in Milan. The IPO raises about $80 million, which founder Leonardo Del Vecchio keeps for himself; the listing later lets Luxottica use its shares to acquire other brands.
Luxottica Acquires LensCrafters via U.S. Shoe Takeover
Luxottica acquires U.S. Shoe Corporation in a $1.4 billion hostile takeover, primarily to obtain LensCrafters, North America's largest optical retail chain. This is Luxottica's first major retail acquisition, giving a frame manufacturer direct control over consumer-facing stores. Many independent opticians and rival chains dropped Luxottica as a supplier, but Luxottica raised its share of frame revenue at LensCrafters from 5% in 1995 to 43% by the end of 1996.
Luxottica Launches EyeMed Vision Care Subsidiary
In the same year it buys Ray-Ban from Bausch & Lomb, Luxottica launches EyeMed Vision Care as its managed vision care subsidiary, four years after acquiring LensCrafters. The insurer gives the frame maker and retailer a way to influence where plan members buy glasses.
Luxottica Acquires Ray-Ban from Bausch & Lomb for $640M
Luxottica purchases Ray-Ban and associated brands (Killer Loop, Revo, Arnette) from Bausch & Lomb for $640 million. Ray-Ban, then in decline with glasses selling at gas stations for $19, is repositioned as a premium brand through artificial scarcity and premium retail placement. By 2014, Ray-Ban revenue grows eightfold to EUR 2.065 billion, demonstrating how monopoly control enables premium pricing on products costing $4-15 to manufacture.
Luxottica Acquires Sunglass Hut for $653M
Luxottica agrees to acquire Sunglass Hut International for $653 million including debt, taking over 1,300 Sunglass Hut stores and 430 Sunglass Hut-Watch Station combination stores. This gives Luxottica the world's largest sunglass retail chain. Within months, Luxottica uses its new retail leverage against Oakley, demanding lower wholesale prices and threatening reduced orders.
Luxottica Buys Managed Vision Care Firm First American Health Concepts
Through an indirect subsidiary, Luxottica acquires First American Health Concepts, then a leading U.S. provider of managed vision care plans, for about $23.5 million net of cash, weeks after closing its Sunglass Hut purchase. The deal expands the managed vision care business run under EyeMed.
Luxottica Uses Sunglass Hut to Pressure Oakley
After buying Sunglass Hut, Oakley's biggest customer, Luxottica tells Oakley it wants significantly lower wholesale prices or it will reduce orders and push its own brands. Within months Oakley tells shareholders the talks have gone badly and Luxottica is slashing its orders, and Oakley's stock immediately loses more than a third of its value.
EyeMed Raises Exam Fees About 25% to Court Providers
After acquiring Eye Care Plan of America, EyeMed, described as the managed vision care arm of Luxottica/LensCrafters, raises the exam fees it pays providers by an average of 25% nationwide from October 1, pushing typical routine exam reimbursements to $50-$60 as it competes with VSP to attract more doctors, including ophthalmologists.
Luxottica 2001 Sales Reach $2.8B as Vertical Integration Pays Off
Following the LensCrafters, Ray-Ban and Sunglass Hut acquisitions, Luxottica's 2001 sales reach $2.8 billion, up 27% from 2000, with earnings of $290 million; both sales and earnings have risen every year since 1992. Analysts credit the move into North American retail with eliminating middlemen from the supply chain.
California Class Action Names EyeMed Over LensCrafters Exam Practices
A proposed class action filed in San Francisco Superior Court against Luxottica, LensCrafters and EYEXAM of California, with remaining claims also against EyeMed Vision Care, alleges violations of California's medical-confidentiality law and of state rules on relationships among optical retailers, frame and lens makers and optometrists, plus false advertising. The plaintiffs seek an injunction that would bar eye exams inside California LensCrafters stores.
Luxottica Signs Ten-Year Prada License, After January Versace Deal
Luxottica signs a ten-year exclusive license (2003-2013) to produce and distribute Prada and Miu Miu eyewear, expecting about EUR 120 million in sales in the first 12 months; it had signed a similar ten-year Versace license in January 2003. Deals like these put more designer names under Luxottica's control while the Luxottica name stays off the product, so consumers buying 'Prada' or 'Versace' glasses generally do not know they are Luxottica products.
Luxottica Acquires Cole National After Unconditional FTC Clearance
Luxottica completes its acquisition of Cole National Corporation at $27.72 per share, adding Pearle Vision, Cole's licensed optical departments in Target and Sears stores, and Cole Managed Vision. The FTC, which had reviewed the deal, lets it go forward unconditionally, further consolidating U.S. optical retail under Luxottica.
Cole Managed Vision Folded Into EyeMed
A year after buying Cole National, Luxottica integrates Cole's managed vision care system with its own, leaving EyeMed as the single brand for the combined plans; renewals and new sales of Cole Managed Vision business now go through EyeMed. The same deal brought Pearle Vision and the Target, Sears and BJ's optical departments under Luxottica.
Luxottica Acquires Oakley for $2.1 Billion
Luxottica agrees to acquire Oakley for about $2.1 billion in cash ($29.30 per share), an 18% premium over Oakley's 30-day average share price, and completes the deal in November 2007. The purchase ends years of hostility dating to 2001, when Luxottica cut Oakley orders after buying Sunglass Hut, and adds Oakley's brands and retail chains, including Oliver Peoples, to Luxottica's portfolio.
LensCrafters Settles California Medical-Privacy Class Action
The San Francisco Superior Court gives final approval to a settlement of the 2002 class action over LensCrafters' in-store eye exams, covering about 1.6 million Californians examined at LensCrafters who bought eyewear the same day between 1998 and 2008. Plaintiffs alleged LensCrafters and its affiliated exam company misused patients' medical and prescription information; class members get $30 cash or vouchers, with upwards of $20 million expected to be paid out. LensCrafters denied wrongdoing.
Consumer Blogger Accuses LensCrafters of Bait-and-Switch Lens Upselling
A consumer blogger recounts two visits to LensCrafters in which staff repeatedly pushed upgrades (featherweight lenses, anti-reflective coating and 'Advanced View Progressive' lenses) that they could not explain or demonstrate; a call to a second LensCrafters store produced the same answers. He calls it a bait-and-switch and buys elsewhere.
Warby Parker Founded to Challenge Luxottica Monopoly
Warby Parker's four co-founders, who met as MBA students at Wharton, launch the company to sell prescription glasses directly to consumers from $95 a pair, cutting out middlemen and markups in an industry dominated by Luxottica. Demand far exceeds expectations, with waitlists of 20,000 people; CNBC later reported that the company hit its first-year sales targets within three weeks of launch.
LensCrafters Rolls Out AccuFit With 'Five Times More Accurate' Claims
LensCrafters rolls out the AccuFit Digital Measurement System around 2011, marketing it as measuring eyes 'five times' more accurately than traditional pupillary-distance methods. Class actions filed in 2017 allege the claims are false because lenses are still made with decades-old methods, and that the pitch induced customers to buy higher-priced LensCrafters eyewear; the eventual settlement class covers purchases from September 2013 to September 2023.
60 Minutes Exposes Luxottica Eyewear Monopoly
CBS 60 Minutes airs a segment with Lesley Stahl revealing how Luxottica controls half a billion eyewear consumers worldwide. A Wall Street Journal columnist describes the appearance of market competition as an 'optical illusion' comparing it to 'fake competition.' The segment brings mainstream public attention to the ownership connections between seemingly independent brands and retailers.
Luxottica EyeMed Reaches Second-Largest US Vision Insurer Status
EyeMed becomes the second-largest vision benefits company in the United States, growing from a niche Luxottica subsidiary into a major insurance player with millions of members. This growth directly serves the shareholder extraction model: each new EyeMed member represents a customer steered into the Luxottica retail ecosystem where the parent captures margins at every step from frame manufacturing to point of sale.
Essilor and Luxottica Announce $49 Billion Merger
Luxottica and Essilor announce a merger worth $49 billion, combining the world's largest frame maker (owner of Ray-Ban, Oakley, major retail chains and the vision insurer EyeMed) with the largest lens maker. Antitrust experts warn about the combined company's power over the industry.
Class Action Alleges LensCrafters Uses Fictitious Lens Prices
A proposed class action (Seegert v. LensCrafters, S.D. Cal.) against LensCrafters, Luxottica Retail North America and Luxottica Group alleges that LensCrafters continuously offers a percentage discount on prescription lenses with any frame purchase, shows only the post-discount prices on in-store signs, and reveals the 'regular' lens price only on the receipt. The complaint alleges the lenses are never actually sold at that regular price, so the advertised savings are fictitious.
Luxottica Retail Plans 208 Layoffs in Memphis
Luxottica Retail North America notifies Tennessee labor officials that more than 208 workers at its facility in Memphis's Hickory Hill area will lose their jobs on December 31, 2017, as Luxottica prepares for its merger with Essilor.
FTC Clears Essilor-Luxottica Merger Without Conditions
The FTC unanimously closes its investigation of the Essilor-Luxottica merger without conditions after a year-long review that examined more than one million documents and interviewed over 100 market participants, concluding the evidence did not show the deal would substantially lessen competition. The combined company spans lenses, frames, brands, retail and managed vision care (EyeMed).
EssilorLuxottica Formally Created
EssilorLuxottica is formally created on 1 October 2018, combining Luxottica's retail and brand empire with Essilor's lens manufacturing and technology portfolio; the combined company commands more than a quarter of global eyewear value sales. EyeMed's role as insurance arm now steers members toward a more complete vertically integrated chain than ever before.
Post-Merger Governance Crisis Erupts Between Founders
A power struggle breaks out between Luxottica founder Leonardo Del Vecchio, who holds 31% of voting rights in EssilorLuxottica, and former Essilor CEO Hubert Sagnieres. Del Vecchio's holding company Delfin accuses Essilor executives of violating the merger agreement, while Sagnieres accuses Del Vecchio of trying to take control of the group without paying shareholders a premium. The merger terms had the two co-manage until 2021, with a new CEO to be chosen by the end of 2020.
LensCrafters Premium AR Coating Complaints Emerge
Customers report that LensCrafters' Premium AR anti-reflective coating, for which they paid as much as $400, starts coming off in as little as six months; replacements sometimes develop the same problem, and customers say they were not told the coating would deteriorate. Charging premium prices for coatings that fail quickly is a dark pattern in the EyeMed retail ecosystem.
EyeMed Data Breach Exposes 2.1 Million Members
An attacker compromises an EyeMed enrollment email account via phishing, accessing six years of sensitive patient data including Social Security numbers, medical diagnoses, and health insurance information. The breached mailbox was shared by nine employees, had weak password controls and no multifactor authentication. The breach ultimately costs EyeMed $12.6 million across four settlements.
FTC Sends 28 Eyeglass Rule Warning Letters Over Prescription Withholding
FTC staff send 28 warning letters to eyeglass prescribers over potential violations of the Eyeglass Rule, which requires them to give patients a copy of their prescription after a refractive exam, without extra fees, waivers or a requirement to buy glasses. Withheld prescriptions keep patients buying where they were examined, including at in-network retailers such as LensCrafters and Pearle Vision.
EssilorLuxottica Completes GrandVision Acquisition
EssilorLuxottica completes the acquisition of GrandVision from HAL Optical Investments at EUR 28.42 per share, adding 7,000+ optical stores across 40+ countries. The European Commission requires divestitures of 351 stores in Belgium, Italy, and the Netherlands as conditions for approval. The deal further consolidates global optical retail under one entity.
IndustriALL Files OECD Complaint Over Anti-Union Tactics
IUE-CWA, AFL-CIO, IndustriALL, and UNI file a formal complaint under OECD Guidelines alleging Luxottica deployed aggressive anti-union tactics at its McDonough, Georgia distribution center. Allegations include mandatory captive-audience meetings, anti-union websites, use of an employee app to send anti-union messages, and hiring outside anti-union consultants to intimidate workers.
EssilorLuxottica Moves Hundreds of Jobs Out of Mason, Ohio
After the Essilor merger, EssilorLuxottica consolidates marketing jobs from Luxottica's North American headquarters in Mason, Ohio, into New York and other corporate functions into Dallas. Luxottica's Mason headcount had already fallen from about 1,900 at the 2018 merger to about 1,500; the company says nearly every affected employee was offered a similar role with relocation support. EyeMed stays in Mason.
NY Attorney General Settles with EyeMed for $600K
New York Attorney General Letitia James announces a $600,000 agreement with EyeMed over the 2020 data breach affecting 98,632 New York residents. The settlement reveals that EyeMed failed to implement multifactor authentication, used a shared password for a sensitive enrollment email account, and retained years of unnecessary personal data. EyeMed agrees to security improvements.
Leonardo Del Vecchio Dies, Milleri Assumes Dual CEO/Chairman Role
Luxottica founder Leonardo Del Vecchio dies at 87. Francesco Milleri, already CEO, is appointed Chairman the next day, combining both roles. Del Vecchio's will divides Delfin, the family holding company that owns about 32% of EssilorLuxottica, equally among eight heirs (his wife, six children and a stepson) at 12.5% each, creating a complex succession.
NY DFS Fines EyeMed $4.5M for Cybersecurity Failures
The New York Department of Financial Services imposes a $4.5 million penalty on EyeMed for violations of its Cybersecurity Regulation stemming from the 2020 data breach. DFS finds that EyeMed failed to implement sufficient cybersecurity controls including MFA, data retention limits, and adequate risk assessments. This is the second New York state penalty for the same breach.
EyeMed Pays $2.5M in Multistate Data Breach Settlement
New Jersey, Florida, Pennsylvania, and Oregon reach a $2.5 million multistate settlement with EyeMed over the 2020 breach. The consolidated investigation found EyeMed's security practices inadequate for the volume of protected health information it handled. This is the third government settlement, bringing total regulatory penalties to $7.6 million.
Fathmath v. EssilorLuxottica Class Action Filed
A proposed federal class action filed in the Northern District of California accuses EssilorLuxottica and 48 co-defendants of conspiring to inflate eyewear prices by up to 1,000%. The complaint alleges EyeMed enters anticompetitive agreements with thousands of providers to channel millions of patients into buying overpriced EssilorLuxottica eyewear, controlling over 80% of American optometrists.
Brown v. EssilorLuxottica Antitrust Complaint Filed
A second major antitrust class action (Brown v. EssilorLuxottica), filed in the District of Minnesota with EyeMed as a defendant, alleges EssilorLuxottica controls over 80% of the U.S. premium-branded eyewear market. It describes EyeMed as the second-largest U.S. vision benefits company with nearly 72 million members, alleges EssilorLuxottica controls over 83% of optometrists through EyeMed, and says EyeMed's provider rules restrict discounts on high-end brand frames.
FTC Updates Eyeglass Rule to Mandate Prescription Release
The FTC finalizes updates to the Eyeglass Rule, whose long-standing core requirement is that prescribers give patients their prescription after a refractive exam. Citing continued non-compliance, the update requires prescribers with a financial interest in selling eyewear to obtain the patient's signed confirmation of receipt and keep it for three years. The rule takes effect September 24, 2024.
EssilorLuxottica Acquires Supreme Streetwear for $1.5B
EssilorLuxottica agrees to buy Supreme from VF Corp for $1.5 billion in cash, $600 million less than VF paid for the brand in 2020. The acquisition signals capital allocation toward brand accumulation rather than improving vision care services or reducing eyewear costs. The deal expands the EssilorLuxottica portfolio beyond eyewear into lifestyle streetwear.
EssilorLuxottica Buys Back Up to 4 Million Shares (~EUR 850M)
EssilorLuxottica runs a program to buy back up to 4 million of its own shares between July 29, 2024 and October 29, 2025, worth about EUR 850 million by S&P Global Ratings' calculation. The buybacks return capital to shareholders while, per the AOA, vision plans paid optometrists $35-$90 per eye exam in 2020, sometimes below Medicaid rates.
LensCrafters AccuFit $39M Settlement Approved
Judge Pamela K. Chen of the Eastern District of New York grants final approval of a $39 million settlement of the certified class action alleging LensCrafters falsely marketed AccuFit as 'five times more accurate' than traditional methods to sell higher-priced prescription lenses. The settlement covers U.S. customers fitted with AccuFit who bought glasses between September 2013 and September 2023.
LensCrafters Fake Discount Class Action Filed
A proposed class action (Velasquez v. Luxottica of America) filed in California state court alleges LensCrafters continuously advertises '40% off' or '50% off' prescription lenses bought with frames, so the 'sales' are not real discounts, and artificially inflates 'retail' prices to exaggerate customers' savings. The suit highlights how EyeMed members steered to LensCrafters can encounter inflated reference prices.
EyeMed's 2025 Extras Steer Members to Pearle Vision and glasses.com
EyeMed's added benefits for 2025, as announced to University of Kentucky employees, include $50 off a complete pair at Pearle Vision and an extra $30 toward anti-reflective lenses at glasses.com, both EssilorLuxottica retail channels, plus up to $1,000 toward LASIK at named partner centers.
Italian Authority Censures Luxottica for Anti-Union Conduct
The OECD's Italian National Contact Point, in a Final Statement published in late December 2024 and publicized by the unions in February 2025, finds that Luxottica rejected the conciliator's recommendations on fair union organizing and caused the breakdown of a six-month conciliation by insisting U.S. law was the only relevant standard. The unions' complaint concerned captive-audience meetings, anti-union consultants and an anti-union website at the McDonough, Georgia logistics center.
AOA Board Accuses EyeMed of Clawbacks and Bad Faith
The American Optometric Association's Board of Trustees writes to EyeMed's president calling the company a 'significant and growing barrier' to care, citing a 2024 AOA poll in which 40% of doctors named EyeMed the biggest barrier to quality care. The letter lists unjustified clawbacks from small and mid-sized practices, tying of participation, shifting explanations of compliance with state laws, refusal of contracting transparency and 'legal and lobbyist warfare' against state optometric associations.
Federal Court Dismisses Eyewear Antitrust Class Actions
Judge Mary Kay Vyskocil of the SDNY dismisses both direct and indirect purchaser antitrust lawsuits against EssilorLuxottica, ruling that plaintiffs offered an 'implausible and contrived' definition of the premium eyewear market. The ruling effectively shields EssilorLuxottica from the most significant legal challenge to its monopoly position. Plaintiffs receive one final chance to amend by October 17, 2025.
EyeMed Presses Arkansas Optometrists to Sign New Contracts Under Act 142
After Arkansas' vision benefit manager law (Act 142) took effect in August 2025 with a Medicare-based reimbursement floor, EyeMed emails hundreds of Arkansas optometrists in October telling them to sign a new provider agreement within 30 days to stay compliant, without identifying the changes. EyeMed later says core terms had not changed and that it does not believe the Medicare-based requirement applies to routine eye exams; 91% of doctors who got the email told the state association they felt pressured to sign, and its 2026 provider manual favors billing codes outside the Medicare fee schedule.
EyeMed Settles Data Breach Class Action for $5M
EyeMed agrees to pay $5 million to settle the consolidated class action (Tate v. EyeMed) over the 2020 phishing breach; the settlement wins preliminary approval in the Southern District of Ohio and also requires security changes such as stronger multifactor authentication and shorter mailbox retention. It brings breach-related payments to $12.6 million across four settlements.
Direct Purchasers Drop Eyewear Antitrust Claims; Indirect Purchasers Appeal
After the September 2025 dismissal, the individual direct-purchaser plaintiffs, including Fathmath and Brown, stipulate to dismissal with prejudice of their claims against EssilorLuxottica, EyeMed and the other defendants, so-ordered on November 3, 2025. The indirect-purchaser plaintiffs had filed a notice of appeal to the Second Circuit on October 24, 2025.
EssilorLuxottica Posts Record 2025 Results, Proposes EUR 4 Dividend
EyeMed's parent reports 2025 revenue of EUR 28.49 billion (up 11.2% at constant exchange rates), adjusted net profit of EUR 3.16 billion and record free cash flow of EUR 2.8 billion, and proposes a EUR 4.00 dividend per share with a scrip option.
Founder's Son Quits EssilorLuxottica Roles, Calls Leadership Distant
Leonardo Maria Del Vecchio resigns as Ray-Ban chairman and chief strategy officer effective August 31, writing to Chairman and CEO Francesco Milleri that management has become 'distant' and 'impersonal' toward staff. He keeps his 12.5% stake in the family holding Delfin, whose eight heirs have still not agreed how to execute the founder's will; on September 9 the board unanimously reaffirms its confidence in Milleri.
EssilorLuxottica Launches Buyback of Up to 5 Million Shares
Days after the founder's son's resignation, EssilorLuxottica mandates an investment services provider to buy back up to 5,000,000 of its shares under authority granted at its April 2026 annual meeting, citing confidence in its value creation.
Court Gives Final Approval to EyeMed's $5M Breach Settlement
Judge Douglas R. Cole of the Southern District of Ohio grants final approval of the $5 million Tate v. EyeMed settlement over the 2020 breach, awarding class counsel about $1.67 million in fees and $775,266 in settlement administration costs, closing the last of the four breach settlements.
Evidence (47 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (8 entries)
Checked 92 items + prose. 34 verified, 38 corrected (8 date-only), 16 re-sourced, 4 removed. Invented: a 1998 'FTC clears Luxottica' event (no such review; source was about 2018), a 2006 governance event with specifics that appear nowhere, and an 'AI nightmare' customer quote. Major fixes: four breach settlements, not five; Eyeglass Rule update added confirmations, not automatic release; D- BBB rating stale (now A+); Oakley not 'weakened' in 2007 (18% premium, not 16%); Brown complaint allegations mixed up with Fathmath's; misdated events (AR coating complaints 2019 not 2004; Mason job moves 2021 not 2016; fake-discount suit 2024 not 2020; licensing began 1988 not 1981); EyeMed was not set up by Luxottica in Mason in 1988; Del Vecchio had eight heirs; AI-written AInvest source replaced; VSP alternative wrongly called conflict-free.
62→53. Since Feb 2026 (and the prior 12 months): AOA letter naming EyeMed a barrier to care (Aug 2025), EyeMed contract ultimatums and narrow reading of Arkansas Act 142 (Oct 2025-Jan 2026), eyewear antitrust suits dismissed with direct purchasers dropping claims and indirect purchasers appealing (Sep-Nov 2025), $5M breach settlement final approval (Sep 2026), record 2025 parent results, a new buyback (Aug 2026) and the founder's son's resignation (Aug 2026). D1 6→5 (correction: D- BBB rating and invented quote removed; complaints are complaint-site level), D2 8→7 (recalibration: vocal provider anger, clawbacks and competition with own retail fit 6-7; lock-in with no alternative not shown, antitrust allegations dismissed), D3 6→5 (recalibration: rising buybacks/dividends, no layoffs-with-buybacks), D4 7→5 (recalibration: financial OON penalty and employer choice, no data/purchase lock-in; also dropped the unsupported claim that Essilor lens brands create product-level lock-in with no alternative supplier), D5 7→5 (recalibration: EyeMed discloses its Luxottica affiliation; opacity is in payment rules and ownership marketing, not extreme), D6 5→4 (recalibration: EyeMed's own patterns rest on complaint-site reports; upselling is retailer conduct), D8 8→7 (correction: 40% U.S. glasses share not 60%, '80% of optometrists' is an allegation, Oakley not 'weakened'; no ruling against EyeMed). Eras: first era re-dated 1988→1999-01-01 (EyeMed Vision Care launched as Luxottica subsidiary per FundingUniverse; 1988 is only EyeMed's own claim) and relabeled 'Managed Care Arm Launch'; 'Retail Chain Consolidation' (2001) and 'Brand Monopoly Completed' (2007) merged, re-dated to 2004-10-04 (Cole National acquisition, Cole Managed Vision folded into EyeMed) and relabeled 'Cole Network Merger'; 'Essilor Mega-Merger' kept; 'Post-Founder Entrenchment' re-dated 2022-07-01→2020-06-24 (EyeMed breach) and relabeled 'Breach and Lawsuits'; current era re-dated from assessment date 2026-02-15 to 2025-08-21 (AOA letter) and relabeled 'Provider Standoff'. Trajectory stable→worsening (provider conflict escalated; parent returns rising). Milestone 'EyeMed Launched' relabeled as stated origin; added 1999 launch and 2001 First American milestones. Category note: EyeMed is a vision insurer; an insurance/health-plan guide may fit better than Eyewear.
Checked 17 removed/trimmed claims: 0 restored, 3 partly restored, 14 confirmed removed, 0 already present. Partly restored: Warby Parker four co-founders and first-year sales targets in three weeks (CNBC 2024-09-28); added Seegert v. LensCrafters (S.D. Cal., filed 2017-07-05) fictitious-lens-price suit, the real source of the dropped 'fictitious retail prices' claim (the 'buy one, get one' detail is only a generic example in the complaint, not alleged of LensCrafters, so it stays out); added 2017-10-30 Memphis layoffs of 208 Luxottica Retail workers (INVISION), the real content of the misdated '200+ jobs' claim. Confirmed removed: 1998 FTC non-action, 2006 governance/part-time claims, Glassdoor layoff review, $4-15 unit cost and Agordo same-factory claim, Luxottica founding EyeMed in Mason in 1988, 'regardless of consumer preference', Oakley 'discounted price', Prada/Versace same-factory and 1,000% markup, EyeMed-benefits editorial, 600+ factories/150+ brands/13,500+ stores, 'millions of customers' in AccuFit (no class size in settlement docs), both Eyeglass Rule editorial claims, Yelp review count.
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).
Added 3 timeline events for coverage gaps (D5 1961-1988, D10 1988-2001, D9 2001-2007)
VSP described as 'member-owned cooperative' — more accurately a 'doctor-governed nonprofit' (lost tax-exempt status 2003). Core point (not owned by EssilorLuxottica) remains valid. Warby Parker pricing and store count confirmed accurate.